LIFE SCIENCES INSIGHTS
Insights and strategic perspectives
Expert perspectives on evidence generation, market access, HEOR, real-world evidence, pricing strategy, and payer insights, curated for life sciences teams across pharma, biotech, and medical device companies.
Latest insight
MFN One Year On: Taking Stock of US Drug Pricing
Tim Wright, our Executive Vice President for Access and Pricing, revisits the predictions on most-favored nation (MFN) pricing he made following the Executive Order, examines what has materialized, and considers what may lie ahead for GENEROUS, GUARD and GLOBE.
Featured strategic insights
A curated selection of recent Genesis Research Group perspectives, payer research, webinars, and expert commentary shaping evidence, access, and commercialization decisions across pharma and biotech.
Navigating Strategies for Comparative Effectiveness, from Trials to Real-world Evidence
On 19 May at ISPOR 2026, our HEOR and real-world evidence teams presented a discussion on the topic of comparative effectiveness.
Understanding GLOBE and GUARD in Most-Favored-Nation Pricing
Tim Wright explains key considerations around GLOBE and GUARD in most-favored-nation pricing and what these models may mean for access and pricing teams.
Defining a Healthcare Ecosystem-Driven Value Strategy for Your Asset
Our ISPOR webinar explores how to anchor your asset’s value story in the broader healthcare ecosystem, aligning evidence, access, and stakeholder priorities…
Meeting the Resource Challenge: Why Biotechs Need a Different Kind of Partner
Watch HealthEconomics.com’s interview with David W. Miller on the distinctive challenges biotech companies face when developing evidence, securing market access, and engaging key stakeholders.
Introducing The Vector: How are US Payers Thinking About AI?
In the first issue of The Vector, Genesis Research Group surveyed US payers to understand how they are thinking about AI and its role in evidence, access, and healthcare decision-making.
MFN Pricing: More Fun to Navigate, A European Roadmap to Success
At ISPOR Europe 2025, Tim Wright, EVP, Access & Pricing, outlined a roadmap for navigating Most Favoured Nation pricing, from establishing a US anchor price to applying value-based approaches.
Is HEOR Losing Clout in Pharma?
Lynn Okamoto and Priti Jhingran examine whether HEOR is losing influence in pharma and how the discipline can be repositioned for broader impact.
Market access and pricing strategy
Explore Genesis perspectives on pricing pressure, payer expectations, IRA developments, MFN pricing, reimbursement strategy, and the evolving access environment facing pharma and biotech teams.
Understanding GLOBE and GUARD in Most-Favored-Nation Pricing
Tim Wright explains key considerations around GLOBE and GUARD in most-favored-nation pricing and what these models may mean for access and pricing teams.
ISPOR Webinar: Defining a Healthcare Ecosystem-Driven Value Strategy for Your Asset
Our webinar explores how to anchor your asset’s value story in the broader healthcare ecosystem, aligning evidence, access, and stakeholder priorities.
ISPOR 2025 Presentation: Is IRA Becoming America’s HTA?
The IRA Medicare drug price negotiation program introduces a negotiation mechanism for US drug pricing with HTA-like features. Is IRA a de facto HTA body?
In-Depth Analysis of RPR-Powered Payer Research Into How the IRA’s Maximum Fair Prices Are Reshaping the Market
The Inflation Reduction Act is setting new benchmarks for pharmaceutical pricing through Medicare’s maximum fair prices. Download our analysis of RPR-powered payer research…
Toward a US HTA? Examining IRA’s Emerging Role, A Conversation with The Evidence Base
Originally published by The Evidence Base in both video and written format, this conversation explores whether the IRA is pushing the US toward an HTA-like model.
Most-Favored-Nation Pricing: First Video Interview with Tim Wright
In the first interview of our MFN pricing series, Tim Wright shares early perspectives on what most-favored-nation pricing could mean for US access and pricing teams.
Understanding Payer Perceptions of Health Inequalities in HTA and Reimbursement Decision-Making
The Evidence Base recently featured a deep dive analysis of this ISPOR 2024 presentation exploring payer perceptions of health inequalities in HTA and reimbursement decisions.
World EPA Congress: Shining the Light on Vaccine Market Access
In March 2024, Genesis Research Group’s Katrin Nather and Tijana Ignjatovic presented at the World EPA Congress on vaccine market access.
Anticipating Pricing and Reimbursement for Newly Approved Products Prior to HTA Decisions
Tijana Ignjatovic, MA, PhD, Executive Director, Access & Pricing, applies the case study of Minjuvi to explore pricing and reimbursement considerations before HTA decisions.
Stay ahead of evidence, access, and market trends
Sign up to receive Genesis Research Group thought leadership, expert videos, webinar invitations, and the latest perspectives on RWE, HEOR, market access, payer strategy, and evidence generation.
Real-world evidence and external control arms
Perspectives on real-world data, real-world evidence, epidemiology, external control arms, regulatory evidence, HTA submissions, and the use of RWE to support decision-making.
Comparative effectiveness: Queries and clarifications
At ISPOR 2026, our team presented on the topic of ‘Navigating Strategies for Comparative Effectiveness from Trials to Real-World Evidence’. In this short Q&A, they answer a few of the questions that commonly arise on this important topic.
ISPOR Webinar: The Value of ECAs for Regulatory & HTA Evidence Needs
In October 2025, ISPOR hosted a webinar featuring experts from Genesis Research Group and other independent organizations on the value of External Control Arms across regulatory and HTA environments.
Turning Real-World Data Into Decisions That Change Patient Lives: A Conversation
Katherine Donegan and Allie Sosinsky discuss how real-world data can be translated into decisions that change patient lives.
The Role of ECAs in Drug Development and Considerations for Success
Read our external control arm contribution to the July/August issue of ISPOR’s Value & Outcomes Spotlight, written by Alexandra Z. Sosinsky, Craig S. Parzynski, and Deborah Casso.
Webinar: Fit-for-Purpose Matchmaking: a Data Selection and RWE Approach
In 2024, we presented a webinar featuring Carole Longson MBE on the topic of “Fit-for-purpose matchmaking: a data selection and RWE approach for both regulatory and HTA audiences”
ISPOR Presentation: External Control Arms for Regulatory and HTA Agencies
In May 2023, Jen Wogen and Craig S. Parzynski presented at ISPOR 23 on “Developing Fit-for-Purpose External Control Arms to Optimize Submissions to Regulatory and Health Technology Assessment Agencies.”
FDA on Real-World Data/Evidence for Regulatory Decisions
Alexandra Sosinsky explores FDA perspectives on real-world data and evidence for regulatory decisions.
HEOR and evidence strategy
Explore Genesis Research Group’s perspectives on HEOR, evidence strategy, evidence generation planning, stakeholder validation, value demonstration, and the changing role of evidence in life sciences decision-making.
Prevalance of Obesity and Related Conditions and GLP-1 Use in Medicare Fee-for-Service Beneficiaries
Our recent real‑world evidence (RWE) study on GLP‑1 receptor agonists (GLP-1 RA), obesity and type 2 diabetes in the Medicare population has been published in Diabetes, Obesity and Metabolism.
ISPOR 2025 Presentation: Is IRA Becoming America’s HTA?
The IRA Medicare drug price negotiation program introduces a negotiation mechanism for US drug pricing with HTA-like features. Is IRA a de facto HTA body?
Toward a US HTA? Examining IRA’s Emerging Role, A Conversation with The Evidence Base
Originally published by The Evidence Base in both video and written format, this conversation explores whether the IRA is pushing the US toward an HTA-like model.
ISPOR’s 2026–2027 HEOR Trends Report: The Era of Evidence Judgment
In response to ISPOR’s 2026–2027 HEOR Trends report, David Miller, CEO of Genesis Research Group, explores why evidence judgment is becoming central to HEOR’s future.
Speak with our experts
Have a question about one of our articles, webinars, or presentations? Our RWE, HEOR, market access, and evidence strategy specialists can help you explore the implications for your asset, evidence plan, or commercialization strategy.
Stakeholder and payer insights
Explore content on payer research, stakeholder validation, RPR-powered insights, evidence generation plans, and the role of stakeholder insights and engagement in market access and evidence strategy.
Accelerating the Generation of Payer Insights and Evidence
Priti Jhingran and Tijana Ignjatovic present a HealthEconomics.com webinar on how actionable payer insights can support evidence generation that is meaningful to payers, HTA, and medical decision-makers.
Introducing The Vector: How are US payers thinking about AI?
In the first issue of The Vector, Genesis Research Group used RPR to survey US payers to understand how they are thinking about AI and its role in evidence, access, and healthcare decision-making.
Stakeholder Validation of Evidence Generation Plans
At the World EPA Congress in March 2023, Priti Jhingran, VP, Evidence Strategy, delivered a presentation on “Stakeholder Validation of Evidence Generation Plans (EGPs) to Achieve Optimal Access.”
The Vector 2: Is AI Shaping Coverage Decision Workflows?
In our second issue, we employed RPR to survey 33 payers across 11 non‑US markets to understand how renewed US interest in Most‑Favored‑Nation (MFN) drug pricing could reshape pricing, reimbursement, and access globally.
Interviews and explainers
Learn more about the Genesis approach to evidence, insights and strategy, our partnership model, and our technology platforms.
EVID AI Full-spectrum Evidence Synthesis Platform
Learn more about EVID AI, a platform built by Genesis Research Group for rapid evidence queries, targeted reviews, literature surveillance, and end-to-end SLRs.
2025 Outlook: Key Trends Reshaping Life Sciences & Healthcare
Read David W. Miller’s article exploring key trends reshaping life sciences and healthcare.
An Introduction to the Flexible Integrated Team Engagement Model
Our Flexible Integrated Team, or FIT, engagement model represents a paradigm shift in how companies engage with pharmaceutical, biotech, and medical device research partners.
ITN Business Interviews CEO David W. Miller
ITN Business invited Genesis Research Group to contribute to “Advancing Healthcare,” a news-style program featuring key opinion leaders confronting healthcare industry challenges.
Discover How Genesis Research Group ‘Innovates Differently’
CEO David W. Miller explains what Genesis means when we say we help life sciences clients “Innovate differently” and transform the way they engage with research partners.
Examples of recent conference posters
Click the dots to see more posters.
Explore related expertise
Many of the perspectives above connect directly to Genesis Research Group’s core capabilities across evidence generation, HEOR, RWE, market access, payer insights, and technology-enabled research.
Use the links below to explore how our teams support evidence, access, and launch decisions across the product lifecycle.
Headquarters:
HOBOKEN
111 River Street, Suite 1120
Hoboken, New Jersey 07030, US
